A multinational Phase 3 extension trial of adjunctive cenobamate reported sustained seizure reductions across adult focal seizure subtypes, including notable seizure-free rates. The update reinforces cenobamate’s durability profile beyond initial treatment windows and supports continued development and optimization of regimen strategies in real-world focal epilepsy populations.